The genes involved in innate immunity face special challenges that other genes do not. For example, in order to target invading viruses, the immune system needs to distinguish between viral ("non-self") components and "self" components that are meant to be in the host. Complicating this task is the wide assortment of potential pathogens that the host may encounter, combined with the ability of most pathogens to readily evolve to escape the host's immune system. This "moving target" requires evolutionary innovation on the part of the host, which is a tall order for vertebrates because they evolve sluggishly.
Now, in eLife, Matthew Daugherty of the Fred Hutchinson Cancer Research Center (FHCRC) and co-workers report how they have used a combination of phylogenetic sleuthing and a novel assay in yeast to explore the evolution of a family of antiviral proteins called IFIT proteins (Daugherty et al., 2016). These proteins are components of the innate immune system in mammals (Fensterl and Sen, 2015).
When a virus is detected, a signaling protein called interferon is released and it induces an antiviral state by upregulating a whole slew of interferon-stimulated genes. IFIT genes are among the most highly upregulated of these genes, and IFIT proteins target a wide range of viruses (Diamond and Farzan, 2013). It is known that IFIT genes are encoded by a complex multigene locus that varies among different mammalian lineages: for example, a common mouse has six intact copies of IFIT-like genes, whereas a rat has four (Liu et al., 2013). However, despite their importance to innate immunity, there is much we do not know about IFIT proteins.
One puzzle involves the ability of an IFIT protein previously known as IFIT1 to distinguish between cellular (mammalian) mRNAs and viral mRNAs. Mammalian mRNA advertises its selfness by adding a methyl group to the first ribose sugar of the mRNA molecule to produce a "cap1" structure; the unmethylated mRNA molecule is said to have a "cap0" structure (Figure 1; Banerjee, 1980). However, many viruses have evolved ways to fly under the radar either by "snatching" cap1 structures from host mRNAs, or by encoding a methyltransferase enzyme that allows them to make their own cap1 structures (Hyde and Diamond, 2015).
IFIT1 and IFIT1B both inhibit the growth of budding yeast (Saccharomyces cerevisiae; top row, middle and right). Co-expressing human Cap1-methyltransferase (which converts cap0-mRNA to cap1-mRNA by …
This disguise appears to work against mouse IFIT1 protein, which exclusively targets cap0 mRNAs, leaving cap1 mRNAs unscathed (Diamond, 2014). Human IFIT1 protein, by contrast, is not tricked by the disguise and targets both cap0 and cap1 viral mRNAs. This suggests that human IFIT1 protein recognizes viral mRNA by a different and as-yet-unknown means. A simple explanation for this difference could be that functional specialization, perhaps driven by challenges from different pathogens, drove the IFIT1 gene to diverge in the mouse and human lineages. This would make the IFIT1 genes orthologs.
Daugherty and co-workers – Aaron Schaller and Harmit Malik, both from FHCRC, and Adam Geballe from FHCRC and the University of Washington School of Medicine – examined this assumption by comparing the IFIT locus among a wide panel of mammalian genomes. This analysis pointed to a gene duplication event that occurred at the IFIT1 locus early in mammalian evolution, more than 100 million years ago. This means that mouse IFIT1 and human IFIT1 are paralogs (caused by a gene duplication event) rather than orthologs (caused by a speciation event), so the authors renamed the mouse gene IFIT1B.
Armed with this new insight into the relationship between human IFIT1 and mouse IFIT1B, Daugherty et al. demonstrated that these two paralogs indeed have distinct functions. To do this, they made use of the fact that budding yeast produces only cap0 structures (Banerjee, 1980). When they expressed mouse IFIT1B in yeast, it targeted cap0 mRNA, in turn inhibiting growth of the yeast, as expected. Growth was rescued when human cap1-methyltransferase was co-expressed with IFIT1B (Figure 1). Human IFIT1, on the other hand, behaved differently. Like mouse IFIT1B, it also inhibited cap0 mRNA and inhibited the growth of the yeast: however, growth was not rescued by co-expressing cap1-methyltransferase. This suggests that IFIT1 depends on something other than cap status to find its target mRNAs. Interestingly, orthologs of IFIT1B from two primates – gibbons and African green monkeys – exhibited the same cap0-targeting behavior as mouse IFIT1B, despite rodents and primates having diverged more than 100 million years ago. Human IFIT1B, by contrast, has lost this particular function.
This study illustrates how a family of vertebrate genes involved in pathogen resistance is continually shaped by the dynamic nature of the multigene locus in which it resides. Such loci frequently undergo duplication, recombination, and gene conversion events (Eirín-López et al., 2012; Nei et al., 1997) that can significantly alter the immune repertoire of various species. Gene duplication events, in particular, can result in relaxed selective pressure on one of the copies, allowing the acquisition of novel functions (Lynch and Conery, 2000; Ohno, 1970). As shown here, such an event is the likely basis for the different functions of IFIT1 and IFIT1B. Indeed, based on this study, these two genes appear to have been the most active of the mammalian IFIT genes, undergoing frequent gene birth and loss, as well as recurrent homogenization.
A number of questions remain unanswered: for instance, how does IFIT1 recognize viral mRNA? And what is the function of human IFIT1B (if, indeed, it has a function)? However, the insights that Daugherty et al. glean from applying phylogenetic analyses to functional studies elegantly underscore the value of multigene loci as facilitators of adaptive responses in the ongoing interplay between vertebrates and their pathogens.
© 2016, Henzy et al.
This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Saprolegnia parasitica is one of the most virulent oomycete species in freshwater aquatic environments, causing severe saprolegniasis and leading to significant economic losses in the aquaculture industry. Thus far, the prevention and control of saprolegniasis face a shortage of medications. Linalool, a natural antibiotic alternative found in various essential oils, exhibits promising antimicrobial activity against a wide range of pathogens. In this study, the specific role of linalool in protecting S. parasitica infection at both in vitro and in vivo levels was investigated. Linalool showed multifaceted anti-oomycetes potential by both of antimicrobial efficacy and immunomodulatory efficacy. For in vitro test, linalool exhibited strong anti-oomycetes activity and mode of action included: (1) Linalool disrupted the cell membrane of the mycelium, causing the intracellular components leak out; (2) Linalool prohibited ribosome function, thereby inhibiting protein synthesis and ultimately affecting mycelium growth. Surprisingly, meanwhile we found the potential immune protective mechanism of linalool in the in vivo test: (1) Linalool enhanced the complement and coagulation system which in turn activated host immune defense and lysate S. parasitica cells; (2) Linalool promoted wound healing, tissue repair, and phagocytosis to cope with S. parasitica infection; (3) Linalool positively modulated the immune response by increasing the abundance of beneficial Actinobacteriota; (4) Linalool stimulated the production of inflammatory cytokines and chemokines to lyse S. parasitica cells. In all, our findings showed that linalool possessed multifaceted anti-oomycetes potential which would be a promising natural antibiotic alternative to cope with S. parasitica infection in the aquaculture industry.
Polyamines are biologically ubiquitous cations that bind to nucleic acids, ribosomes, and phospholipids and, thereby, modulate numerous processes, including surface motility in Escherichia coli. We characterized the metabolic pathways that contribute to polyamine-dependent control of surface motility in the commonly used strain W3110 and the transcriptome of a mutant lacking a putrescine synthetic pathway that was required for surface motility. Genetic analysis showed that surface motility required type 1 pili, the simultaneous presence of two independent putrescine anabolic pathways, and modulation by putrescine transport and catabolism. An immunological assay for FimA—the major pili subunit, reverse transcription quantitative PCR of fimA, and transmission electron microscopy confirmed that pili synthesis required putrescine. Comparative RNAseq analysis of a wild type and ΔspeB mutant which exhibits impaired pili synthesis showed that the latter had fewer transcripts for pili structural genes and for fimB which codes for the phase variation recombinase that orients the fim operon promoter in the ON phase, although loss of speB did not affect the promoter orientation. Results from the RNAseq analysis also suggested (a) changes in transcripts for several transcription factor genes that affect fim operon expression, (b) compensatory mechanisms for low putrescine which implies a putrescine homeostatic network, and (c) decreased transcripts of genes for oxidative energy metabolism and iron transport which a previous genetic analysis suggests may be sufficient to account for the pili defect in putrescine synthesis mutants. We conclude that pili synthesis requires putrescine and putrescine concentration is controlled by a complex homeostatic network that includes the genes of oxidative energy metabolism.